Treatment of Bile Acid Malabsorption With Liraglutide

NCT03955575 on ClinicalTrials.gov · last registry update 2022-06-03

Finished 10 March 2021, after enrolling 52 people. Primary outcome, as filed: Change in stool fequency.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Filip Krag Knop
Sponsor type: Other
Enrollment: 52
Started: 2019-03-07
Primary completion: 2021-03-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in stool fequency

Conditions studied

Bile Acid Malabsorption

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.